Table 1.

Characteristics of patients with COVID-19 and diabetes remotely managed with CGM

	Patient 1	Patient 2	Patient 3	Patient 4
Age (years)	26	63	76	82
Sex	F	F	M	M
Diabetes type	Type 1	Type 2	Newly diagnosed type 2	Type 2
COVID-19 severity	Mild	Moderate	Severe	Severe
Need for oxygen support	Room air	Oxygen 4 L/min	Ventilator	High-flow oxygen
Additional comorbidities	None	Ischemic CVA, HTN	HTN, NAFLD, CKD, hypothyroidism	HTN and dyslipidemia status post mechanical AVR, osteoporosis, past smoker
Diabetes treatment	CSII	MDI	MDI	MDI
Glucose management before CGM
Mean blood glucose tests per day	4.7	2.8	3.75	3.0
Mean ± SD blood glucose (mg/dL)	127 ± 33	382 ± 188	192 ± 79	183 ± 14
Glucose management with remote real-time CGM
Mean blood glucose tests per day	2.3	1.5	1.8	2.1
Mean ± SD blood glucose (mg/dL)	127 ± 32	200 ± 54	168 ± 63	145 ± 45
Time with transmitted data (%)	96.3	72.3	90.8	97.2
TIR >250 mg/dL (%)	0.0	13.2	13.7	1.7
TIR 180–250 mg/dL (%)	5.7	56.7	29.0	14.2
TIR 110–180 mg/dL (%)	60.4	30.0	32.7	64.2
TIR 70–110 mg/dL (%)	33.1	0.1	23.9	12.6
TIR <70 mg/dL (%)	0.8	0.0	0.7	5.6
TIR <54 mg/dL (%)	0.0	0.0	0.0	1.7

AVR, aortic valve replacement; CSII, continuous subcutaneous insulin infusion; CVA, cerebrovascular accident; HTN, hypertension; MDI, multiple daily injections of insulin; NAFLD, nonalcoholic fatty liver disease; TIR, time in range.